Abstract
Gamma-hydroxybutyrate (GHB) is a central nervous system depressant endogenously produced and also employed as a recreational drug of abuse since the 90s, attracting notable attention particularly in those cases of drug facilitated sexual assault (DFSA). The implication of GHB among DFSA cases generates numerous concerns, making the interpretation of the toxicological findings often significantly difficult. In this review the Authors have explored GHB behaviour in ante-mortem and post-mortem specimens, taking into consideration its endogenous production, the post mortem interval, the time between sampling and analysis, the storage conditions (temperature and presence/absence of preservatives) and the usefulness of alternative matrices such as hair, bile and vitreous humour. Moreover, the cut-off values currently recommended in forensic toxicology in order to discriminate between endogenous and exogenous levels have been examined.
Keywords: Gamma-hydroxybutyric acid (GHB), cut-off values, endogenous and post-mortem behaviour, post-mortem interval (PMI), storage conditions.
Recent Patents on Biotechnology
Title:GHB in Biological Specimens: Which Cut-off Levels Should be Taken into Consideration in Forensic Toxicological Investigation?
Volume: 8 Issue: 3
Author(s): Francesco Paolo Busardo and Chrystalla Kyriakou
Affiliation:
Keywords: Gamma-hydroxybutyric acid (GHB), cut-off values, endogenous and post-mortem behaviour, post-mortem interval (PMI), storage conditions.
Abstract: Gamma-hydroxybutyrate (GHB) is a central nervous system depressant endogenously produced and also employed as a recreational drug of abuse since the 90s, attracting notable attention particularly in those cases of drug facilitated sexual assault (DFSA). The implication of GHB among DFSA cases generates numerous concerns, making the interpretation of the toxicological findings often significantly difficult. In this review the Authors have explored GHB behaviour in ante-mortem and post-mortem specimens, taking into consideration its endogenous production, the post mortem interval, the time between sampling and analysis, the storage conditions (temperature and presence/absence of preservatives) and the usefulness of alternative matrices such as hair, bile and vitreous humour. Moreover, the cut-off values currently recommended in forensic toxicology in order to discriminate between endogenous and exogenous levels have been examined.
Export Options
About this article
Cite this article as:
Paolo Busardo Francesco and Kyriakou Chrystalla, GHB in Biological Specimens: Which Cut-off Levels Should be Taken into Consideration in Forensic Toxicological Investigation?, Recent Patents on Biotechnology 2014; 8 (3) . https://dx.doi.org/10.2174/1872208309666150504143155
DOI https://dx.doi.org/10.2174/1872208309666150504143155 |
Print ISSN 1872-2083 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4012 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting the Toll of Drug Abuse: The Translational Potential of Toll-Like Receptor 4
CNS & Neurological Disorders - Drug Targets Solution NMR Study of the Transmembrane Domain of Single-Span Membrane Proteins: Opportunities and Strategies
Current Protein & Peptide Science The CRF Family of Neuropeptides and their Receptors - Mediators of the Central Stress Response
Current Molecular Pharmacology Bioinformatic Analysis Reveals Key Genes and Pathways in Aging Brain of Senescence-accelerated Mouse P8 (SAMP8)
CNS & Neurological Disorders - Drug Targets Stereoselective Synthesis and Antiproliferative Activity of Monoterpene-Fused 2- Imino-1,3-oxazines
Current Organic Synthesis Liposomes: Novel Drug Delivery Approach for Targeting Parkinson’s Disease
Current Pharmaceutical Design Approaches and Resources for Prediction of the Effects of Non-Synonymous Single Nucleotide Polymorphism on Protein Function and Interactions
Current Pharmaceutical Biotechnology Soft Computing Techniques for the Protein Folding Problem on High Performance Computing Architectures
Current Drug Targets An Association of Virus Infection with Type 2 Diabetes and Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Urinary Albumin to Creatinine Ratio as Potential Biomarker for Cerebral Microvascular Disease
Current Neurovascular Research A Pulmonary Perspective on GASPIDs: Granule-Associated Serine Peptidases of Immune Defense
Current Respiratory Medicine Reviews Gene Therapy Approaches to Ataxias
Current Gene Therapy Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) “Self-Nonself” Peptides in the Design of Vaccines
Current Pharmaceutical Design Neurogenesis in Alzheimers Disease: A Realistic Alternative to Neuronal Degeneration?
Current Signal Transduction Therapy ATP-Binding Cassette Efflux Transporters in Human Placenta
Current Pharmaceutical Biotechnology The Ambivalent Role of Apoptosis in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis
Current Pharmaceutical Design Anti-convulsant Action and Attenuation of Oxidative Stress by Citrus limon Peel Extracts in PTZ and MES Induced Convulsion in Albino Rats
Central Nervous System Agents in Medicinal Chemistry Neuroimaging Outcomes in Studies of Cognitive Training in Mild Cognitive Impairment and Early Alzheimer’s Disease: A Systematic Review
Current Alzheimer Research Which Treatment for Nonalcoholic Fatty Liver Disease?
Mini-Reviews in Medicinal Chemistry